Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Status: Enrolling
Updated:  2/22/2018
Gen Hosp Univ Vienna Dept Cardiology
mi
from
Vienna,
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Status: Enrolling
Updated: 2/22/2018
Gen Hosp Univ Vienna Dept Cardiology
mi
from
Vienna,
Click here to add this to my saved trials
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Status: Enrolling
Updated:  2/22/2018
Barnes-Jewish Hosp/Wash Univ School of Med
mi
from
Saint Louis, MO
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Status: Enrolling
Updated: 2/22/2018
Barnes-Jewish Hosp/Wash Univ School of Med
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Autonomic Nervous System and Obesity
The Autonomic Nervous System and Obesity
Status: Enrolling
Updated:  2/27/2018
Vanderbilt University
mi
from
Nashville, TN
The Autonomic Nervous System and Obesity
The Autonomic Nervous System and Obesity
Status: Enrolling
Updated: 2/27/2018
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Withings Pulse Wave Velocity and Blood Pressure Study
Withings Pulse Wave Velocity and Blood Pressure Study
Status: Enrolling
Updated:  2/27/2018
Scripps Translational Science Institute
mi
from
La Jolla, CA
Withings Pulse Wave Velocity and Blood Pressure Study
Withings Pulse Wave Velocity and Blood Pressure Study
Status: Enrolling
Updated: 2/27/2018
Scripps Translational Science Institute
mi
from
La Jolla, CA
Click here to add this to my saved trials
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study
Status: Enrolling
Updated:  3/2/2018
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study
Status: Enrolling
Updated: 3/2/2018
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study
Status: Enrolling
Updated:  3/2/2018
Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
mi
from
Los Angeles, CA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study
Status: Enrolling
Updated: 3/2/2018
Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease
Status: Enrolling
Updated:  3/2/2018
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease
Status: Enrolling
Updated: 3/2/2018
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated:  3/2/2018
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated: 3/2/2018
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated:  3/2/2018
VA Connecticut Health Care System (Newington)
mi
from
Newington, CT
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated: 3/2/2018
VA Connecticut Health Care System (Newington)
mi
from
Newington, CT
Click here to add this to my saved trials
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated:  3/2/2018
VA Connecticut Health Care System
mi
from
West Haven, CT
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated: 3/2/2018
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated:  3/2/2018
Edith Nourse Rogers Memorial Veterans Hospital, Bedford
mi
from
Bedford, MA
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated: 3/2/2018
Edith Nourse Rogers Memorial Veterans Hospital, Bedford
mi
from
Bedford, MA
Click here to add this to my saved trials
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated:  3/2/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated: 3/2/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Click here to add this to my saved trials
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated:  3/2/2018
VA Medical Center Manchester
mi
from
Manchester, NH
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated: 3/2/2018
VA Medical Center Manchester
mi
from
Manchester, NH
Click here to add this to my saved trials
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated:  3/2/2018
VA Medical Center, Providence
mi
from
Providence, RI
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
VISN Collaborative for Improving Hypertension Management With ATHENA-HTN
Status: Enrolling
Updated: 3/2/2018
VA Medical Center, Providence
mi
from
Providence, RI
Click here to add this to my saved trials
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study
Status: Enrolling
Updated:  3/5/2018
David Geffen School of Medicine at University of California Los Angeles
mi
from
Los Angeles, CA
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study
Status: Enrolling
Updated: 3/5/2018
David Geffen School of Medicine at University of California Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oral Nitrite in Adults With Metabolic Syndrome and Hypertension
An Open-Label Study of Oral Nitrite in Adults With Metabolic Syndrome and Hypertension
Status: Enrolling
Updated:  3/5/2018
Montefiore Hospital of UPMC
mi
from
Pittsburgh, PA
Oral Nitrite in Adults With Metabolic Syndrome and Hypertension
An Open-Label Study of Oral Nitrite in Adults With Metabolic Syndrome and Hypertension
Status: Enrolling
Updated: 3/5/2018
Montefiore Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% q.d. and b.i.d. Compared to Timolol Maleate Ophthalmic Solution, 0.5% b.i.d. in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated:  3/9/2018
Aerie Pharmaceuticals
mi
from
Bedminster, NJ
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% q.d. and b.i.d. Compared to Timolol Maleate Ophthalmic Solution, 0.5% b.i.d. in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated: 3/9/2018
Aerie Pharmaceuticals
mi
from
Bedminster, NJ
Click here to add this to my saved trials
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety of AR-13324 Ophthalmic Solution, 0.02% QD & BID Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated:  3/9/2018
Nancy Ramirez
mi
from
Bedminster, NJ
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety of AR-13324 Ophthalmic Solution, 0.02% QD & BID Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated: 3/9/2018
Nancy Ramirez
mi
from
Bedminster, NJ
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Cardiology PC
mi
from
Birmingham, AL
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Cardiology PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Cardiovascular Institute of the South
mi
from
Houma, LA
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Cardiovascular Institute of the South
mi
from
Houma, LA
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Columbia University Medical Center
mi
from
New York, NY
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Wellmont CVA Heart Institute
mi
from
Kingsport, TN
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Wellmont CVA Heart Institute
mi
from
Kingsport, TN
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Cardiovascular Research Institute of Dallas
mi
from
Dallas, TX
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Cardiovascular Research Institute of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Aspirus Heart & Vascular Institute
mi
from
Wausau, WI
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Aspirus Heart & Vascular Institute
mi
from
Wausau, WI
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
University of Maryland
mi
from
Baltimore, MD
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Tufts Medical Center
mi
from
Boston, MA
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated:  3/9/2018
Dallas Medical Center
mi
from
Dallas, TX
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Status: Enrolling
Updated: 3/9/2018
Dallas Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated:  3/9/2018
Aerie Pharmaceuticals
mi
from
Bedminster, NJ
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated: 3/9/2018
Aerie Pharmaceuticals
mi
from
Bedminster, NJ
Click here to add this to my saved trials
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  3/13/2018
Speciality Eyecare Centre
mi
from
Bellevue, WA
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 3/13/2018
Speciality Eyecare Centre
mi
from
Bellevue, WA
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated:  3/13/2018
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated: 3/13/2018
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated:  3/13/2018
Rocky Mountain Lions Eye Inst
mi
from
Aurora, CO
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated: 3/13/2018
Rocky Mountain Lions Eye Inst
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated:  3/13/2018
Eye Care Centers Management/Clayton Eye Center
mi
from
Morrow, GA
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated: 3/13/2018
Eye Care Centers Management/Clayton Eye Center
mi
from
Morrow, GA
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated:  3/13/2018
New York Eye and Ear Infirmary of Mt. Sinai; New York Glaucoma Research Institute
mi
from
New York, NY
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated: 3/13/2018
New York Eye and Ear Infirmary of Mt. Sinai; New York Glaucoma Research Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated:  3/13/2018
Cornerstone Eye Care, Div of Cornerstone Health Care
mi
from
High Point, NC
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated: 3/13/2018
Cornerstone Eye Care, Div of Cornerstone Health Care
mi
from
High Point, NC
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated:  3/13/2018
West Virginia University Eye Institute
mi
from
Morgantown, WV
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated: 3/13/2018
West Virginia University Eye Institute
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated:  3/13/2018
Singapore National Eye Centre; Glaucoma Department
mi
from
Singapore,
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Status: Enrolling
Updated: 3/13/2018
Singapore National Eye Centre; Glaucoma Department
mi
from
Singapore,
Click here to add this to my saved trials
Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement
Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement
Status: Enrolling
Updated:  3/13/2018
Helfgott Research Institute
mi
from
Portland, OR
Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement
Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement
Status: Enrolling
Updated: 3/13/2018
Helfgott Research Institute
mi
from
Portland, OR
Click here to add this to my saved trials
The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension
Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effect of Grape Seed Extract Delivered in a Beverage on Blood Pressure in Individuals With Pre-hypertension.
Status: Enrolling
Updated:  3/15/2018
Clinical Nutrition Research Center
mi
from
Chicago, IL
The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension
Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effect of Grape Seed Extract Delivered in a Beverage on Blood Pressure in Individuals With Pre-hypertension.
Status: Enrolling
Updated: 3/15/2018
Clinical Nutrition Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy
The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Investigator Initiated Trial
Status: Enrolling
Updated:  3/20/2018
Methodist Healthcare, University Hospital
mi
from
Memphis, TN
The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy
The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Investigator Initiated Trial
Status: Enrolling
Updated: 3/20/2018
Methodist Healthcare, University Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging
Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Arterial Hypertension Using Functional Positron Emission Tomography Imaging
Status: Enrolling
Updated:  3/21/2018
Massachusetts General Hospital
mi
from
Boston, MA
Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging
Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Arterial Hypertension Using Functional Positron Emission Tomography Imaging
Status: Enrolling
Updated: 3/21/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Nesiritide in Resistant Hypertension
Novel Peptides in Resistant Human Hypertension
Status: Enrolling
Updated:  3/21/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Nesiritide in Resistant Hypertension
Novel Peptides in Resistant Human Hypertension
Status: Enrolling
Updated: 3/21/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated:  3/21/2018
Novartis Investigator Site
mi
from
Birmingham, AL
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated: 3/21/2018
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated:  3/21/2018
Novartis Investigative Site
mi
from
Jacksonville, FL
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated: 3/21/2018
Novartis Investigative Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated:  3/21/2018
Novartis Investigative Site
mi
from
Knoxville, TN
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated: 3/21/2018
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated:  3/21/2018
Novartis Investigative Site
mi
from
Daytona Beach, FL
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated: 3/21/2018
Novartis Investigative Site
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated:  3/21/2018
Novartis Investigative Site
mi
from
Honolulu, HI
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated: 3/21/2018
Novartis Investigative Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated:  3/21/2018
Novartis Investigative Site
mi
from
Gentofte,
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated: 3/21/2018
Novartis Investigative Site
mi
from
Gentofte,
Click here to add this to my saved trials